Skip to main content

Table 1 Baseline characteristics, length of stay and outcome of the study patients

From: Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study

  TP (n = 15) AVP (n = 15) NE (n = 15) P value
Age, years 67 (60; 71) 66 (60; 74) 64 (59; 72) 0.889
Gender, male 73% 67% 80% 0.717
Body weight, kg 85 (79; 100) 85 (71; 98) 85 (78; 90) 0.612
SAPS II 62 (57; 72) 60 (49; 66) 58 (52; 68) 0.664
Cause of septic shock Necrotizing fasciitis (n = 1) Endocarditis (n = 1) Pancreatitis (n = 4) 0.438
  Pancreatitis (n = 3) Necrotizing fasciitis (n = 2) Peritonitis (n = 6)  
  Peritonitis (n = 5) Peritonitis (n = 6) Pneumonia (n = 5)  
  Pneumonia (n = 6) Pneumonia (n = 6)   
ICU mortality 7/15 8/15 10/15 0.533
ICU length of stay 14 (9; 25) 17 (5; 27) 17(7; 23) 0.878
  1. Data are given as median (25%; 75% range).
  2. AVP = arginine vasopressin; ICU = intensive care unit; NE = norepinephrine; TP = terlipressin; SAPS II = simplified acute physiology score II.